Verrica says pooled Phase 3 analysis shows YCANTH clears molluscum about 4x faster than vehicle
VRCA•Verrica said a pooled analysis of Phase 3 trials found YCANTH cleared molluscum about four times faster than vehicle, with consistent benefits regardless of disease duration. The results are scheduled for presentation at the Fall Clinical Dermatology Conference on October 8-11, 2026.
1. Pooled trial analysis
Verrica said a new pooled analysis of its Phase 3 YCANTH trials found the treatment cleared molluscum contagiosum about four times faster than vehicle, with consistent benefits regardless of how long patients had the disease. The results have not yet been presented and are scheduled for a poster presentation at the Fall Clinical Dermatology Conference on October 8-11, 2026; an encore poster will revisit previously presented Phase 2 VP-315 data on untreated basal cell carcinoma lesions.
